Vical: Collategene gets OK for late-stage trial

Vical's Japanese partner AnGes MG got a special protocol assessment approval from U.S. health regulators for a late-stage clinical trial of Collategene to treat peripheral arterial disease. The SPA provides a company with a written agreement that the design and analysis of the trial are adequate to support a marketing application submission to the FDA, Vical says. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.